Roche gets WHO prequalification for Tocilizumab to treat severe COVID-19 - Medical Dialogues

Retrieved on: 2022-02-12 07:37:13

Tags for this article:

Drugs

Coronaviridae

Medical specialties

Zoonoses

COVID-19 drug development

Monoclonal antibodies

Casirivimab/imdevimab

Roche

SARS-CoV-2 Delta variant

COVID-19

Tocilizumab

Severe acute respiratory syndrome coronavirus 2

Actemra

Roche Pharmaceuticals

Click the tags to see associated articles and topics

Roche gets WHO prequalification for Tocilizumab to treat severe COVID-19 - Medical Dialogues. View article details on HISWAI: https://medicaldialogues.in/news/industry/pharma/roche-gets-who-prequalification-for-tocilizumab-to-treat-severe-covid-19-88462

Excerpt

Basel: Roche has announced that Actemra/RoActemra (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification ...

Article found on: medicaldialogues.in

View Original Article